State Street SPDR S&P Pharmaceuticals ETF
XPH
78 hedge funds and large institutions have $101M invested in State Street SPDR S&P Pharmaceuticals ETF in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 31 reducing their positions, and 9 closing their positions.
1.81% more ownership
Funds ownership: 41.66% → 43.47% (+1.8%)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
1% less funds holding
Funds holding: 79 → 78 (-1)
10% less capital invested
Capital invested by funds: $112M → $101M (-$11.1M)
55% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.99M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.25M |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$719K |
| 4 |
AIC
Ameritas Investment Company
Lincoln,
Nebraska
|
+$565K |
| 5 |
IMC Chicago
Chicago,
Illinois
|
+$552K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
CX Institutional
Auburn,
Indiana
|
-$2.12M |
| 2 |
FCM
Fortis Capital Management
Bellevue,
Washington
|
-$2.07M |
| 3 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$1.65M |
| 4 |
JP Morgan Chase
New York
|
-$1.47M |
| 5 |
CF
Centaurus Financial
Anaheim,
California
|
-$1.35M |
XPH Hedge Fund Activity: Q3 2021 in Review
78 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2021, worth a combined $101M — down 9.9% from $112M a quarter earlier.
Fund positioning in XPH was balanced in Q3 2021: 9 funds opened new positions, 9 closed out, 14 added to existing stakes and 31 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.99M. The largest seller was CX Institutional, cutting an estimated $2.12M.
- 78 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2021, down from 79 in Q2 2021.
- Funds reported $101M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2021, down 9.9% quarter-over-quarter.
- 9 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2021 and 9 closed out, a net change of 0 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2021 was Goldman Sachs, an estimated $8.99M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2021 was CX Institutional, an estimated $2.12M sold.
Based on aggregated 13F filings for Q3 2021.